Ainos, Inc. reports developments tied to its transition toward AI-powered scent intelligence and industrial sensing. The company centers its commercial focus on AI Nose, an electronic olfaction platform that uses sensor arrays and proprietary artificial intelligence models, including its Smell Language Model, to convert volatile organic compound and scent signals into machine-readable Smell ID data.
Recurring news themes include AI Nose commercialization across semiconductor manufacturing, robotics, smart infrastructure, and healthcare-related environments; distribution and deployment relationships; industry classification updates; and financial results connected to the platform. Ainos also maintains a therapeutic-development program around VELDONA, a low-dose oral interferon program targeting rare, autoimmune, and infectious diseases.
Ainos (NASDAQ:AIMD) is scaling AI Nose deployments across semiconductor manufacturing, with front-end and back-end initiatives driving recurring subscription revenue.
Key metrics: ~200 systems planned for front-end wafer fabs in 1Q26, 1,400 Phase 1 systems for ASE completing in 2Q26, generating ≈$2.1M over three years and a potential $10M annual subscription run‑rate if a 20,000‑system roadmap executes.
Ainos (NASDAQ:AIMD) announced continued validation of its AI Nose platform in front-end wafer fabs with ~200 targeted deployments planned in Q1 2026 for technical validation.
It is executing Phase 1 of a 1,400-system back-end deployment worth approximately $2.1 million under a three-year subscription, targeting completion in Q2 2026. The broader roadmap contemplates up to 20,000 systems, which the company says could approach $10 million in annual subscription value, all subject to technical validation and contractual conversion. Management says milestones and subscription activation plans remain unchanged despite market volatility.
Ainos (NASDAQ:AIMD) outlined a phased deployment plan for up to 20,000 AI Nose systems, anchored by a confirmed initial order of 1,400 systems.
The initial order activates recurring subscription revenue under a three-year service structure totaling approximately $2.1 million, and the roadmap states potential annual order values approaching $10 million if fully executed, subject to staged technical validation and formal contractual conversion.
Validation testing is underway in advanced semiconductor front-end fabrication environments to support commercial integration and multi-site industrial scaling.
Ainos (NASDAQ:AIMD) activated a phased industrial deployment roadmap to install up to 20,000 AI Nose units in semiconductor production environments under a strategic framework with ASE Technology Holding.
Phase one includes a confirmed order of 1,400 units under a three-year subscription (~$2.1M), $350,000 in customer deposits, and a target completion by end of Q2 2026. Later phases (5,000 and up to 15,000 units) depend on milestone validation and contractual progression.
Ainos (NASDAQ:AIMD) reported statistically significant interim efficacy from its open-label VELDONA trial in feline chronic gingivostomatitis (FCGS). In six treated cats, mean oral inflammation improved ~38% at Week 6 and ~45% at Week 14, with 66.7% of subjects achieving ≥30% improvement.
Safety signals were absent: liver and renal labs remained stable and VELDONA was well tolerated. Enrollment continues to 12 subjects to assess dose response and durability.
Ainos (NASDAQ:AIMD) began live AI Nose deployments in semiconductor manufacturing after receiving an initial $2.1 million order from a back-end packaging and testing customer. Preparations in the second half of 2025 enabled on-site rollouts that started in January 2026.
Back-end deployments are now operating in live environments generating scent data, while front-end semiconductor pilots advance to broaden use cases and strengthen Ainos' Smell Language Model (SLM).
Ainos (NASDAQ:AIMD) announced a strategic partnership with Mirle to integrate its AI Nose SmellTech into Mirle's mobile and quadruped robotic platforms, extending deployments from commercial buildings into industrial environments such as semiconductor fabs and advanced manufacturing.
The collaboration aims to add chemical sensing to vision and audio, improve early detection of gas leaks and VOCs, and accelerate real-world data collection to scale the Smell ID library and platform capabilities.
Ainos (NASDAQ:AIMD) is advancing its AI Nose SmellTech platform, positioning scent as a native AI data layer through standardized Smell IDs and a proprietary Smell Language Model. The company reported multi-year semiconductor back-end orders of approximately $2.1M for ~1,400 AI Nose units and highlighted robotics partnerships to scale continuous scent data generation in 2026.
The firm's dual-engine architecture separates physical sensing from intelligence-as-a-service (via subsidiary ScentAI) to pursue recurring subscription economics, broader industrial deployments across front-end and back-end semiconductor operations, and accelerated data flywheel growth via robotics partnerships.
Ainos (NASDAQ:AIMD) announced a technology partnership with Mirle Automation on February 2, 2026, to integrate Ainos' AI Nose scent‑digitizing platform into mobile and quadruped robotic platforms.
The collaboration targets inspection, monitoring, and autonomous tasks — detecting VOCs, gas leaks, and chemical anomalies — to boost robotic situational awareness and safety across fabs, manufacturing, healthcare, outdoor inspection, and security applications.
Ainos (NASDAQ:AIMD / AIMDW) will participate in a fireside chat with Water Tower Research on Monday, January 26, 2026 at 11:00 a.m. ET.
The company will discuss its dual-engine SmellTech platform, partnership with Trusval Technology, progress scaling AI Nose technology toward commercial deployment, and strategic priorities for 2026. The event is listen-only and a replay will be posted under "Events" on Ainos' investor relations site.